Form 4: Ligand Pharma Director Sells Shares Under 10b5-1 Plan

Ligand Pharmaceuticals Director John W. Kozarich reported the sale of 467 shares of common stock on January 2, 2026, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Director John W. Kozarich sold a total of 467 shares of Ligand Pharmaceuticals Inc. common stock.
• The sales occurred on January 2, 2026.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2025.
• The shares were sold at weighted-average prices ranging from $186.59 to $192.395 per share.
• Following these transactions, Mr. Kozarich beneficially owns 43,654 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be perceived negatively, the execution under a 10b5-1 plan mitigates concerns about discretionary selling based on new information. The amount sold is also relatively small compared to the remaining holdings.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled, non-discretionary transaction rather than a reaction to new material non-public information.

Negatives

• Insider selling, even under a 10b5-1 plan, reduces the director's direct equity stake in the company.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the general implication of reduced insider ownership.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1.
• The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

This Form 4 filing, detailing an insider stock transaction, does not provide information relevant to broader industry trends or competitive landscape analysis.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, potentially viewed with slight caution, but largely neutral due to the 10b5-1 plan.

Next Steps

• The Reporting Person is obligated to provide detailed information on shares sold at each price within the reported ranges upon request.

Key Dates

Recommendation

The reported insider selling by a director, while a reduction in direct ownership, was executed under a pre-established 10b5-1 trading plan. This suggests the transaction is routine and not based on new, adverse material information. The relatively small number of shares sold (467) compared to the remaining beneficial ownership (43,654) also limits its significance. Therefore, this filing alone does not warrant a change in investment thesis, leading to a 'hold' recommendation.

Keywords

Ligand Pharmaceuticals, LGND, Form 4, Insider Trading, Stock Sale, John W. Kozarich, 10b5-1 Plan, Director Transaction